Background {#S0001}
==========

Acute myeloid leukemia (AML) is a malignant disease of hemopoietic stem cells. It is characterized by clonal expansion of differentiated blasts of myeloid lineage.[@CIT0001] The current version of the WHO classification provides guidance on AML diagnosis, treatment and prognostication.[@CIT0002] The outcome of AML patients is heterogeneous, depending on both patient- and disease-related risk factors. Genomic abnormalities account for at least 60% of the variables in AML prognostication.[@CIT0003] For example, *FLT3-ITD* has a clear correlation with a poor outcome, while mutations in *NPM1* bode a particularly better prognosis.[@CIT0004] The presence of biallelic mutations of *CEBPA* is an independent factor for favorable outcome in AML patients.[@CIT0005] A recent meta-analysis indicated that *IDH1* mutations confer a poorer survival,[@CIT0006] so do genetic aberrations of *TP53*[@CIT0007] or *RUNX1*.[@CIT0008] Genetic factors are incorporated to treatment design because they determine disease sensitivity to treatment as well as the tolerability of therapy.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a strong anti-leukemic effect and it is a commonly used option for AML post-remission consolidation therapy.[@CIT0009] It especially improves the outcomes of patients with poor-risk or intermediate-risk disease.[@CIT0010] Although allo-HSCT can decrease the frequency of relapse and prolong survival, many patients still relapse post-transplant.[@CIT0001] An increasing number of research focusing on post-transplant relapse have pointed out several factors including WBC count at diagnosis,[@CIT0011] cytogenetic risk status,[@CIT0012] initial induction response,[@CIT0013] and most importantly, minimal residual disease (MRD) status at the time of transplantation.[@CIT0014] In the MRD-negative patients who still experience relapse, genetic alterations might play an even bigger role in leukemogenesis and prognostication.[@CIT0015]

The dedicator of cytokinesis 1 (DOCK) family is a class of the atypical Rho guanine nucleotide exchange factors (GEFs).[@CIT0016] As a major Rac GEF, DOCK proteins are involved in various cellular processes, such as cell adhesion, cell migration, actin cytoskeleton, and tumorigenesis.[@CIT0017],[@CIT0018] Sze-Hwei Lee, et al, have discovered that high expression of *DOCK1* implied poor prognosis in AML patients.[@CIT0019] However, it is yet to be determined whether the expression level of *DOCK1* has prognostic value in AML patients undergoing allo-HSCT. In this study, we will focus on the prognostic significance of *DOCK1* in a cohort of AML patients undergoing allo-HSCT and discuss its clinical implications.

Patients and methods {#S0002}
====================

Patients {#S0002-S2001}
--------

A group of 71 de novo AML patients (41 males, 30 females) from The Cancer Genome Atlas (TCGA) (<https://cancergenome.nih.gov/>) database, who had undergone allo-HSCT and had available *DOCK1* expression data, were included in the study. TCGA database was originated from a single institution tissue banking protocol that was approved by the Washington University Human Studies Committee. All patients were between ages 18 and 88 and had previously untreated de novo AML. The samples were collected between November of 2001 and March of 2010. Clinical characteristics, as well as risk groups and the frequencies of known recurrently mutated genes, were highly representative of adult patients with de novo AML. The patients were treated in accordance with NCCN guidelines ([www.nccn.org](http://www.nccn.org)), with an emphasis on enrollment in therapeutic clinical trials whenever possible. Those patients with intermediate or unfavorable risk underwent allogeneic stem cell transplant if they were medically fit for transplantation, and if a suitably matched donor was available. Next-generation sequencing was utilized for detecting genetic mutations. Written informed consent was obtained from each patient approved by the Human Research Ethics Committee of Washington University. Clinical and molecular information at diagnosis were collected. All the data was publicly available on the website of the TCGA database.

Statistical analysis {#S0002-S2002}
--------------------

Descriptive statistics were used to summarize demographics, clinical and molecular information. Continuous variables were described in the form of the median with range. The Mann--Whitney *U* test was used for comparing two groups of numeric variables, and chi-square analysis was applied to the comparison of categorical variables. The clinical endpoint of this study was overall survival (OS), which was defined as the time from diagnosis to death or was censored at the last follow-up. The OS rate was calculated using the Kaplan--Meier method, and the survival curves were plotted. The log-rank test was used to analyze significant differences between survival distributions. A cox proportional hazard model was applied to univariable and multivariable analyses to assess possible prognostic factors. The relapse-free survival (RFS) rate, defined as the time from the date of diagnosis to relapse, was also analyzed. The level of statistical significance was set at *P*\<0.05 for all analyses. SPSS software version 20.0 and GraphPad Prism software version 6.0 were used for all the statistical analyses.

Results {#S0003}
=======

Association of *DOCK1* expression level with demographic characteristics and prognostic factors {#S0003-S2001}
-----------------------------------------------------------------------------------------------

The total of 71 patients was divided into two groups *(DOCK1*^high^ group and *DOCK1*^low^ group) based on the median *DOCK1* expression level. High *DOCK1* expressers were associated with older age (≥60, *P*=0.019), with an average age of 55 compared with 51 in *DOCK1*^low^ group (*P*=0.010). Patients with higher *DOCK1* expression had a lower percentage of peripheral blood (PB) blasts (*P*=0.010) and fewer *IDH1/2* mutations (*P*=0.010). *FLT3-ITD* appeared more frequently in *DOCK1*^high^ patients (*P*=0.051). All the patients with *CEBPA* double mutation were in *DOCK1*^low^ group while *RUNX1* mutations were observed only in *DOCK1*^high^ group (*P*=0.005). There were no differences in other clinical factors including WBC count, FAB subtypes and karyotypes, as well as molecular prognostic features like *TP53, MLL-PTD* and *NPM1* mutations. As for the ratios of relapse, no differences were found between the two groups. There was no difference between the two groups on the transplant status. The summary of the association between *DOCK1* expression level and the demographic and prognostic factors is displayed in [Table 1](#T0003){ref-type="table"}.Table 1Clinical and molecular characteristics of *DOCK1*^high^ and *DOCK1*^low^ patientsCharacteristics*DOCK1*^high^ (n=36)*DOCK1*^low^ (n=35)*U*/*χ^2^P*-valueAge/years, median (range)55 (23--72)51 (18--69)854.0\*0.010Age group/n (%)5.481^§^0.019 \<60 years22 (61.1)30 (85.7) ≥60 years14 (38.9)5 (14.3)Gender/n (%)0.739^§^0.390 Male19 (52.8)22 (62.9) Female17 (47.2)13 (37.1)WBC count/×10^9^/L, median (range)23.35 (0.6--102.5)32.4 (1.2--223.8)506.0\*0.154BM blasts/%, median (range)70 (30--100)71 (34--99)585.5\*0.609PB blasts/%, median (range)41 (0--91)62.5 (5--96)393.0\*0.010FAB subtypes/n (%)9.396^§^0.225 M07 (19.4)2 (5.9)3.022^§^0.151 M19 (25.0)14 (41.2)1.823^§^0.177 M27 (19.4)11 (32.4)1.347^§^0.246 M30 (0.0)1 (2.9)1.043^§^0.493 M48 (22.2)5( 14.7)0.747^§^0.387 M53 (8.3)1 (2.9)1.001^§^0.614 M61 (2.8)0 (0.0)0.986^§^1.000 M71 (2.8)0 (0.0)0.986^§^1.000Karyotype/n (%)8.636^§^0.472 Normal16 (44.4)17 (48.6)0.122^§^0.727 Complex7 (19.4)4 (11.4)0.871^§^0.351 8 Trisomy4 (11.1)2 (5.7)0.668^§^0.674 inv(16)/CBFβ-MYH114 (11.1)1 (2.9)1.847^§^0.357 11q23/MLL2 (5.6)1 (2.9)0.319^§^1.000 −7/7q-1 (2.8)2( 5.7)0.378^§^0.614 t(15;17)/PML-RARA0 (0.0)1 (2.9)1.043^§^0.493 t(9;22)/BCR-ABL11 (2.8)1 (2.9)0.000^§^1.000 t(8;21)/RUNX1-RUNX1T10 (0.0)1 (2.9)1.043^§^0.493 Others1 (2.8)5 (14.3)3.038^§^0.107Risk/n (%)1.574^§^0.455 Good4 (11.1)3 (8.8)0.102^§^1.000 Intermediate18 (50.0)22 (64.7)1.544^§^0.214 Poor14 (38.9)9 (26.5)1.222^§^0.269*FLT3-ITD*5.937^§^0.015 Presence13 (36.1)4 (11.4) Absence23 (63.9)28 (88.6)*NPM1*0.378^§^0.539 Mutation8 (22.2)10 (28.6) Wild type28 (77.8)25 (71.4)*CEBPA*9.273^§^0.010 Single mutation0 (0.0)5 (14.3) Double mutation0 (0.0)3 (8.6)3.222^§^0.115 Wild type36 (100.0)27 (77.1)9.273^§^0.002*DNMT3A*2.124^§^0.145 Mutation6 (16.7)11 (31.4) Wild type30 (83.3)24 (68.6)*IDH1/2*6.601^§^0.010 Mutation4 (11.1)13 (37.1) Wild type32 (88.9)27 (62.9)*WT1*2.129^§^0.260 Mutation6 (16.7)2 (5.7) Wild type30 (83.3)33 (94.3)*RUNX1*8.765^§^0.005 Mutation8 (22.2)0 (0.0) Wild type28 (77.8)35 (100.0)*MLL-PTD*1.001^§^0.614 Presence3 (8.3)1 (2.9) Absence33 (91.7)34 (97.1)*NRAS/KRAS*1.522^§^0.260 Mutation2 (5.6)5 (14.3) Wild type34 (94.4)30 (85.7)*TET2*0.001^§^1.000 Mutation2 (5.6)2 (5.7) Wild type34 (94.4)33 (94.3)*TP53*4.121^§^0.115 Mutation4 (11.1)0( 0.0) Wild type32 (88.9)35 (100.0)*KIT*3.045^§^0.239 Mutation3 (8.3)0 (0.0) Wild type33 (91.7)3 5(100.0)*PTPN11*2.029^§^0.199 Mutation1 (2.8)4 (11.4) Wild type35 (97.2)31 (88.6)*PHF6*1.001^§^0.614 Mutation3 (8.3)1 (2.9) Wild type33 (91.7)34 (97.1)Relapse0.029^§^0.864 Yes24 (66.7)24 (68.6) No12 (33.3)11 (31.4)HSCT0.145^§^0.930 Haplo1 (2.8)1 (2.8)0.000^§^1.000 Sib allo19 (52.8)20 (57.1)0.144^§^0.705 MUD16 (44.4)14 (40.0)0.137^§^0.712Transplant status/n (%)1.735^§^0.420 CR119 (52.8)21 (60.0)0.376^§^0.540 CR25 (13.9)7 (20.0)0.472^§^0.492 Others12 (33.3)7 (20.0)1.610^§^0.205[^1][^2]

Higher expression level of *DOCK1* indicated shorter OS in AML patients undergoing allo-HSCT {#S0003-S2002}
--------------------------------------------------------------------------------------------

Univariate and multivariate analysis using cox proportional hazard models synthesized possible prognostic elements including *DOCK1* expression level (high vs low), age (≥60 vs \<60 years), WBC (≥30 vs \<30×10^9^/L), risk stratification (poor vs non-poor) and genetic mutation like *FLT3-ITD, NPM1, DNMT3A, CEBPA* double mutation, *IDH1* and *RUNX1*. The results are shown in [Tables 2](#T0004){ref-type="table"} and [3](#T0005){ref-type="table"}.Table 2Univariate analysis for OSVariablesOSHR (95% CI)*P*-value*DOCK1* (high vs low)2.940 (1.655--5.211)\<0.001Age (≥60 vs \<60 years)1.406 (0.769--2.571)0.268WBC (≥30 vs \<30×10^9^/L)0.986 (0.571--1.702)0.959Risk(poor vs non-poor)1.290 (0.719--2.313)0.393*FLT3-ITD* (negative vs positive)0.600 (0.319--1.131)0.114*NPM1* (wild vs mutated)1.243 (0.651--2.372)0.510*DNMT3A* (wild vs mutated)0.794 (0.421--1.498)0.477*CEBPA* double mutation0.656 (0.159--2.705)0.559*IDH1/2* (wild vs mutated)1.275 (0655--2.483)0.475*RUNX1* (wild vs mutated)0.410 (0.190--0.887)0.024Transplant in CR1/2 (yes vs no)0.615 (0.337--1.124)0.114[^3] Table 3Multivariate analysis for OSVariablesOSHR (95% CI)*P*-value*DOCK1* (high vs low)3.027 (1.304--7.025)0.010Age (≥60 vs \<60 years)0.977 (0.492--1.942)0.947WBC (≥30 vs \<30×10^9^/L)0.615 (0.291--1.300)0.203Risk (poor vs non-poor)1.282 (0.605--2.717)0.517*FLT3-ITD* (negative vs positive)0.435 (0.183--1.036)0.060*NPM1* (wild vs mutated)1.285 (0.483--3.422)0.616*DNMT3A* (wild vs mutated)0.479 (0.216--1.064)0.071*CEBPA* double mutation2.519 (0.456--13.908)0.289*IDH1/2* (wild vs mutated)0.921 (0.351--2.416)0.867*RUNX1* (wild vs mutated)0.725 (0.257--2.045)0.543Transplant in CR1/2 (yes vs no)0.459 (0.216--0.976)0.043[^4]

Univariate analysis and Kaplan--Meier survival curve both revealed that patients undergoing allo-HSCT in *DOCK*1^high^ group had a shorter OS ([Table 2](#T0004){ref-type="table"}, [Figure 1](#F0001){ref-type="fig"}, both *P*\<0.001). Mutations in *RUNX1* also had an adverse effect on OS ([Table 2](#T0004){ref-type="table"}, *P=*0.024). The result of multivariate analysis further demonstrated the unfavorable effect of high *DOCK1* expression ([Table 3](#T0005){ref-type="table"}, *P*=0.010). Multivariate analysis also showed that patients who received a transplant in CR1/2 had longer OS ([Table 3](#T0005){ref-type="table"}, *P*=0.043). *RUNX1, FLT3-ITD* and *NPM1* were not correlated with the OS in AML patients undergoing allo-HSCT in our cohort. The results of univariate and multivariate analysis of RFS, as well as the Kaplan-Meier curve, were provided in [Tables S1](#ST0001) and [S2](#ST0002) and [Figure S1](#SD1){ref-type="supplementary-material"} in the Supplementary Appendix. Figure 1Kaplan--Meier curves of overall survival (OS). Patients in *DOCK1*^high^ group have shorter OS than those in *DOCK1*^low^ group.

Discussion {#S0004}
==========

In our study, overexpression of *DOCK1* can shorten OS in AML patients undergoing allo-HSCT, implying that allo-HSCT cannot eliminate the negative effect of *DOCK1* overexpression. As an important prognostic marker, *DOCK1* might be a potential therapeutic target for AML treatment.

Sze-Hwei Lee, et al[@CIT0019] showed that higher *DOCK1* expression was associated with many other prognostic factors including intermediate-risk cytogenetics. As a curative-intent method, allo-HSCT has a well-documented anti-tumor effect especially on high-risk and intermediate-risk AML patients.[@CIT0020] The prognostic influence of some prognostic mutations can be ameliorated by allo-HSCT.[@CIT0021] For example, Ma Y, et al concluded that allo-HSCT could efficiently reduce relapse and boost survival for patients with *FLT3-ITD* mutation.[@CIT0022] Yang Xu, et al have shown that allo-HSCT could prolong survival in cytogenetically normal AML.[@CIT0023] Our study came to similar conclusions that allo-HSCT could overcome the adverse effect of some prognostic factors, such as *FLT3-ITD, DNMT3A* and *RUNX1*. However, the inferior outcome associated with *DOCK1* overexpression could not be completely overcome by allo-HSCT. Though transplant status in CR1/2 prolongs survival to some extent, the statistical significance still brings the level of *DOCK1* expression to our attention.

Consistent with the previous study,[@CIT0019] our study showed that patients with *DOCK1* overexpression were older and had higher PB blast percentage at diagnosis. But there was no distinct relationship between *DOCK1* expression and karyotype or cytogenetics, probably due to the implementation of allo-HSCT. We found a negative correlation between *DOCK1* expression and frequencies of *FLT3-ITD, RUNX1* mutations in our cohort. Since these were well-defined poor prognostic factors, the negative correlation could further imply that high *DOCK1* expression could be an independent risk factor for AML outcome post-transplant.

As a GEF, DOCK1 plays multiple roles in physiological and pathological conditions. Researches have shown that DOCK1 regulates cell motility and tumor invasion in glioma cell by binding with engulfment and cell motility protein 1 (ELMO1).[@CIT0024],[@CIT0025] Laurin, et al, reported that DOCK1 was a critical regulator in HER2-mediated breast cancer metastasis.[@CIT0018] In human colorectal cancer, DOCK1 was simulated by cortactin, which could promote cell migration and invasion.[@CIT0026] Downregulation of DOCK1 may prevent epithelial--mesenchymal transition in bladder cancer.[@CIT0016] Furthermore, in vivo researches by Tajiri, et al. have demonstrated the effectiveness of targeting DOCK1 in the ras-driven cancer cell.[@CIT0027] Hence, targeted therapy against DOCK1 deserves attention for future anti-cancer drug design. As demonstrated by the current study, the unfavorable effect of *DOCK1* could not be eliminated by allo-HSCT, it would be worth investigating *DOCK1*-targeted therapy in AML patients for post-transplant maintenance.

Our study is limited by sample size and its retrospective nature. A larger cohort study is in need to confirm our findings. Further bench work exploring the role of DOCK1 in leukemogenesis are also imperative.

In conclusion, higher *DOCK1* expression could predict a worse outcome in AML patients and its effect could not be overcome by allo-HSCT. *DOCK1* is a potential anti-leukemia target for AML treatment.
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We analyze the relapse-free survival (RFS) rate using the univariate and multivariate analysis. The log-rank test was used to analyze significant differences between survival distributions. A cox proportional hazard model was applied to univariable and multivariable analyses to assess possible prognostic factors. *DOCK1* expression did not show any significant effect on RFS outcome in uni- and multivariate analysis ([Tables S1](#ST0001) and [S2](#ST0002)). The Kaplan--Meier curve of RFS showed no significance either ([Figure S1](#SD1){ref-type="supplementary-material"}). Figure S1Kaplan--Meier curves of relapse-free survival (RFS). There is no difference between *DOCK1*^high^ group and *DOCK1*^low^ group in the length of RFS. Table S1Univariate analysis for RFSVariablesRFSHR (95% CI)*P*-value*DOCK1* (high vs low)1.264 (0.716-2.233)0.419[^5]Table S2Multivariate analysis for RFSVariablesRFSHR (95% CI)*P*-value*DOCK1* (high vs low)1.242 (0.585--2.634)0.573Age (≥60 vs \<60 years)0.620 (0.276--1.392)0.247WBC (≥30 vs \<30×10^9^/L)1.832 (0.884--3.799)0.104Risk (poor vs non-poor)0.771 (0.353-1.686)0.515*FLT3-ITD* (negative vs positive)0.502 (0.237--1.061)0.071*NPM1* (wild vs mutated)1.910 (0.807--4.520)0.141*DNMT3A* (wild vs mutated)0.981 (0.448--2.146)0.961*CEBPA* double mutation0.474 (0.092--2.450)0.373*IDH1/2* (wild vs mutated)1.002 (0.372--2.700)0.996*RUNX1* (wild vs mutated)1.139 (0.319--4.061)0.841Transplant in CR1/2 (yes vs no)0.866 (0.409--1.832)0.707[^6]

[^1]: **Note:** \*Mann--Whitney *U* test; ^§^chi-square test.

[^2]: **Abbreviations:** WBC, white blood cell; BM, bone marrow; PB, peripheral blood; FAB, French American British; HSCT, hematopoietic stem cell transplantation; Haplo, haploidentical; Allo, allogeneic; MUD, matched unrelated donor; CR, complete remission.

[^3]: **Abbreviations:** OS, overall survival; WBC, white blood cell; CR, complete remission.

[^4]: **Abbreviations:** OS, overall survival; WBC, white blood cell; CR, complete remission.

[^5]: **Abbreviations:** RFS, relapse-free survival; CR, complete remission.

[^6]: **Abbreviations:** RFS, relapse-free survival; WBC, white blood cell; CR, complete remission.
